ERS Genomics
88 Harcourt Street
Dublin 2
Tel: +353-01-539-0082
Website: http://www.ersgenomics.com/
Email: info@ersgenomics.com
About ERS Genomics
ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by co-inventor and co-owner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.
YEAR FOUNDED:
2013
LEADERSHIP:
Scientific Advisor and Co-Founder: Dr. Emmanuelle Charpentier
Chairman of the Board and Co-Founder: Shaun Foy
CEO: Eric Rhodes
TECHNOLOGY:
Please click here for ERS Genomics' technology.
64 articles about ERS Genomics
-
New CRISPR/Cas9 Agreement for ERS Genomics and ATLATL
11/17/2022
ERS Genomics Limited is pleased to announce ATLATL Innovation Centre as its non-exclusive agent for licensing ERS’ intellectual property for commercial and/or research use in China.
-
Global biopharma and life sciences companies provide updates to their businesses and pipelines.
-
ERS Genomics and Cellular Engineering Technologies Enter CRISPR/Cas9 License Agreement
8/17/2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Cellular Engineering Technologies, a biotechnology company specializing in cell manufacturing and contract research services, announced a non-exclusive license agreement granting CET access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
-
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations including Takeda, Origin Therapeutics, ERS Genomics and more.
-
ERS Genomics and Japan SLC Sign CRISPR/Cas9 License Agreement
7/27/2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
ERS Genomics: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third
6/1/2021
ERS Genomics Limited announced that the Japanese Patent Office has rejected arguments filed in opposition to the second Japanese patent filed by Dr. Charpentier, together with The Regents of the University of California and University of Vienna, which covers compositions and methods for use in a variety of eukaryotic cells, in either dual-guide or single-guide format.
-
ERS Genomics and GenScript Biotech Corporation sign CRISPR/Cas9 license agreement
5/12/2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr.
-
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.
-
ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement
4/19/2021
ERS Genomics Limited and NUVISAN Innovation Campus Berlin GmbH announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
-
BioSpace Global Roundup, March 11
3/11/2021
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement
3/10/2021
Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models
-
BioSpace Movers & Shakers, March 5
3/5/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Global Roundup: Sofinnova Partners Closes $540 Million Fund for European Biotech Investments
3/4/2021
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
ERS Genomics Expands Team With Appointment of Jon Kratochvil as VP Business Development
3/1/2021
Jon Kratochvil joins as Vice President for Business Development & Licensing for North America
-
Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
-
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement
2/23/2021
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and G+FLAS Life Sciences, Inc., a biotechnology company developing research tools and reagents associated with CRISPR technology, announced a non-exclusive license agreement granting G+FLAS access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
-
Biopharma and life sciences companies from around the globe provide updates on their pipelines and businesses.
-
ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement
2/16/2021
ERS Genomics Limited and ZeClinics announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics’ CRISPR/Cas9 patent portfolio.